A new drug combination therapy has been identified for non-small cell lung cancers. By combining two drugs, lung cancer patients response to immunotherapy can be improved, reveals a new study.
Johns Hopkins Kimmel Cancer Center researchers and colleagues have identified these so-called epigenetic therapy drugs, when used together, achieved robust anti-tumor responses in human cancer cell lines and mice.
During the study, published in the journal iCell,/i a team of researchers led by graduate ...
A new drug combination therapy has been identified for non-small cell lung cancers. By combining two drugs, lung cancer patients response to immunotherapy can be improved, reveals a new study.
Johns Hopkins Kimmel Cancer Center researchers and colleagues have identified these so-called epigenetic therapy drugs, when used together, achieved robust anti-tumor responses in human cancer cell lines and mice.
During the study, published in the journal iCell,/i a team of researchers led by graduate ...